European Union has given its CE Mark approval for a diabetic wound management device developed by global medical devices firm Integra LifeSciences.

The new device called Integra Flowable Wound Matrix 2 is a flowable version of Integra’s wound matrix and helps in filling deep soft tissue and tunnel wounds resulting out of diabetes, such as diabetic foot or foot ulcers.

Integra Flowable Wound Matrix 2, which uses the company’s collagen technology, is claimed to treat partial and full-thickness wounds, pressure and venous ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds and draining wounds.

Following EU’s approval, the company will release the wound management device, which is already in use in the US and Latin America, into the European market.

Integra Skin and Wound EMEA marketing and sales director Marie-Ange Passemard said the company has the ability to meet the demand from centers in Europe that are specialized in chronic wound treatment and witnessing a jump in diabetes-related pathologies.

"This is good news for patients, who will have an alternative to the usual treatment for their wounds," added Passemard.

Integra’s corporate vice president, president – international Debbie Leonetti said, "Integra’s Flowable Wound Matrix now offers surgeons, and patients, a new option for managing these hard-to-access wounds".